COVAX 新冠肺炎疫苗实施计划

10月8日，中国同全球疫苗免疫联盟签署协议，正式加入“新冠肺炎疫苗实施计划”。这是中国秉持人类卫生健康共同体理念、履行自身承诺推动疫苗成为全球公共产品的一个重要举措。

China signed an agreement with Gavi, the Vaccine¹ Alliance, officially joining COVAX on Oct 8. This is an important step China has taken to uphold the concept of a shared community of health for all and to honor its commitment of turning COVID-19 vaccines² into a global public good.

 

中国新冠疫苗研发完成并投入使用后，将作为全球公共产品，为实现疫苗在发展中国家的可及性和可担负性作出中国贡献。

COVID-19 vaccine development and deployment³ in China, when available, will be made a global public good. This will be China’s contribution to ensuring vaccine accessibility and affordability⁴ in developing countries.

——2020年5月18日，习近平在第73届世界卫生大会视频会议开幕式上的致辞

 

中方秉持人类命运共同体理念，愿同各国分享防控有益做法，开展药物和疫苗联合研发，并向出现疫情扩散的国家提供力所能及的援助。

Guided by the vision of building a community with a shared future for mankind, China will be more than ready to share our good practices, conduct joint⁵ research and development of drugs and vaccines, and provide assistance where we can to countries hit by the growing outbreak.

——2020年3月26日，习近平在二十国集团领导人特别峰会上的发言

分享到：